Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05139914 · ClinicalTrials.gov registry record · Phase 4
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
A Phase 4 study, sponsored by Boston University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT05139914 is a Phase 4 study that was terminated before completion, run by Boston University. The registered enrollment target is 4 participants.
The verdict
NCT05139914, a Phase 4 study, was terminated before completion, sponsored by Boston University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the heart and blood vessels. The overarching objective of this mechanistic study is to learn how a Sodium-Glucose Cotransporter-2 (SGT2) inhibitor, dapagliflozin, impacts vascular health in patients with Type 2 Diabetes Mellitus (T2DM). The investigators will compare the changes in vascular health to changes in endothelial cell (EC) phenotype including non-coding RNA (ncRNA) to develop evidence supporting the mechanism of cardiovascular benefit of SGLT2 inhibitors. This study will provide novel information regarding the mechanism of effects of novel treatments for endothelial function and vascular health in patients with T2DM to reduce cardiovascular (CV) risk. The research aims to assess the: * effects of dapagliflozin on EC phenotype. * impact of dapagliflozin on vasodilator function and additional measures of vascular health including arterial stiffness and circulating markers of vascular health.
Interventions
- OTHER Placebo
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2025-02-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05139914
The ClinicalTrials.gov registry entry for NCT05139914 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05139914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05139914 about?
NCT05139914 is a clinical study titled "Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes". Patients with Type 2 Diabetes Mellitus (T2DM) have changes in blood vessel health that can lead to a higher chance of developing heart attacks or strokes. New medications for T2DM including dapagliflozin, which is a Sodium-Glucose Cotransporter-2 inhibitor (SGLT2) inhibitor, may help protect the hea...
What is the current status of trial NCT05139914?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2022-05-31. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT05139914?
The interventions under investigation include: Placebo (OTHER), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT05139914?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.